Cite

HARVARD Citation

    Gore, M. et al. (2017). Sorafenib dose escalation in treatment‐naïve patients with metastatic renal cell carcinoma: a non‐randomised, open‐label, Phase 2b study. BJU international. pp. 846-853. [Online]. 
  
Back to record